

Ana Leo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2663564/publications.pdf>

Version: 2024-02-01

164
papers

9,441
citations

36203

51
h-index

42291

92
g-index

167
all docs

167
docs citations

167
times ranked

13818
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
2	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	9.4	389
3	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
4	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
5	The X chromosome and immune associated genes. <i>Journal of Autoimmunity</i> , 2012, 38, J187-J192.	3.0	277
6	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015, 6, 8019.	5.8	245
7	Definition of human autoimmunity "autoantibodies versus autoimmune disease. <i>Autoimmunity Reviews</i> , 2010, 9, A259-A266.	2.5	210
8	Biliary apoptoses and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. <i>Hepatology</i> , 2010, 52, 987-998.	3.6	194
9	Apoptoses and the biliary specificity of primary biliary cirrhosis. <i>Hepatology</i> , 2009, 49, 871-879.	3.6	193
10	Primary biliary cirrhosis is associated with altered hepatic microRNA expression. <i>Journal of Autoimmunity</i> , 2009, 32, 246-253.	3.0	191
11	Is autoimmunity a matter of sex?. <i>Autoimmunity Reviews</i> , 2008, 7, 626-630.	2.5	172
12	Geoeidemiology, gender and autoimmune disease. <i>Autoimmunity Reviews</i> , 2012, 11, A386-A392.	2.5	144
13	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	1.4	139
14	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
15	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. <i>Scientific Reports</i> , 2016, 6, 25906.	1.6	132
16	Primary biliary cholangitis. <i>Lancet</i> , The, 2020, 396, 1915-1926.	6.3	126
17	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 436-442.	3.0	123
18	The consequences of apoptosis in autoimmunity. <i>Journal of Autoimmunity</i> , 2008, 31, 257-262.	3.0	122

#	ARTICLE	IF	CITATIONS
19	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. <i>Hepatology</i> , 2008, 48, 1906-1912.	3.6	120
20	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	1.8	119
21	Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 153-160.	3.6	116
22	The tumour microenvironment and immune milieu of cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 63-78.	1.9	109
23	Interpreting Serological Tests in Diagnosing Autoimmune Liver Diseases. <i>Seminars in Liver Disease</i> , 2007, 27, 161-172.	1.8	100
24	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	99
25	The immunological potential of galectin-1 and -3. <i>Autoimmunity Reviews</i> , 2009, 8, 360-363.	2.5	96
26	Y chromosome loss in male patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013, 41, 87-91.	3.0	93
27	Role of liver biopsy in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 6041-6052.	1.4	92
28	Autophagy: Highlighting a novel player in the autoimmunity scenario. <i>Journal of Autoimmunity</i> , 2007, 29, 61-68.	3.0	91
29	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
30	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. <i>Clinical Epigenetics</i> , 2015, 7, 61.	1.8	83
31	Primary biliary cholangitis: a comprehensive overview. <i>Hepatology International</i> , 2017, 11, 485-499.	1.9	82
32	Etiopathogenesis of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3328.	1.4	80
33	The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020, 40, 034-048.	1.8	76
34	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012, 13, 461-468.	2.2	75
35	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , 2016, 185, 61-71.	1.1	75
36	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , 2011, 6, 95-102.	1.3	74

#	ARTICLE	IF	CITATIONS
37	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
38	Autoimmunity and Turner's syndrome. <i>Autoimmunity Reviews</i> , 2012, 11, A538-A543.	2.5	73
39	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. <i>Journal of Autoimmunity</i> , 2020, 114, 102511.	3.0	72
40	Shotgun proteomics: Identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. <i>Hepatology</i> , 2014, 60, 1314-1323.	3.6	68
41	B cell depletion therapy exacerbates murine primary biliary cirrhosis. <i>Hepatology</i> , 2011, 53, 527-535.	3.6	66
42	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 176-180.	3.0	64
43	Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. <i>Journal of Autoimmunity</i> , 2012, 38, J193-J196.	3.0	64
44	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013, 46, 81-87.	3.0	64
45	Innate Immunity and Primary Biliary Cirrhosis. <i>Current Molecular Medicine</i> , 2009, 9, 45-51.	0.6	63
46	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
47	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. <i>Hepatology</i> , 2011, 54, 196-203.	3.6	60
48	Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. <i>Hepatology</i> , 2013, 57, 1498-1508.	3.6	58
49	Common Variable Immunodeficiency and Liver Involvement. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 340-351.	2.9	58
50	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. <i>Frontiers in Immunology</i> , 2014, 5, 128.	2.2	57
51	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019, 11, 2971.	1.7	57
52	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. <i>Liver Cancer</i> , 2020, 9, 15-27.	4.2	56
53	Hla class II antigens associated with lupus nephritis in italian SLE patients. <i>Human Immunology</i> , 2003, 64, 462-468.	1.2	54
54	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54

#	ARTICLE	IF	CITATIONS
55	X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. <i>Clinical and Experimental Immunology</i> , 2012, 169, 253-262.	1.1	52
56	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , 2013, 14, 179-186.	2.2	52
57	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020, 73, 453-455.	1.8	51
58	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2366-2368.e3.	2.4	51
59	Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. <i>Journal of Hepatology</i> , 2010, 52, 712-717.	1.8	50
60	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 310-317.	0.4	47
61	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G623-G633.	1.6	46
62	Genetics and Epigenetics of Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 255-264.	1.8	42
63	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	3.6	42
64	Towards common denominators in primary biliary cirrhosis: The role of IL-12. <i>Journal of Hepatology</i> , 2012, 56, 731-733.	1.8	38
65	Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. <i>Cancers</i> , 2020, 12, 2190.	1.7	38
66	Role of Cholangiocytes in Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 273-284.	1.8	37
67	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 1495-1506.	3.6	35
68	Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. <i>Clinical and Experimental Immunology</i> , 2011, 165, 243-250.	1.1	34
69	Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. <i>European Journal of Immunology</i> , 2014, 44, 945-954.	1.6	34
70	High mortality in COVID-19 patients with mild respiratory disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13314.	1.7	34
71	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. <i>Journal of Autoimmunity</i> , 2019, 100, 17-26.	3.0	33
72	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021, 3, 100248.	2.6	33

#	ARTICLE	IF	CITATIONS
73	Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. <i>Journal of Gastroenterology</i> , 2011, 46, 29-38.	2.3	32
74	Geoeidemiology, Genetic and Environmental Risk Factors for PBC. <i>Digestive Diseases</i> , 2015, 33, 94-101.	0.8	32
75	Hepatotoxicity of immune check point inhibitors: Approach and management. <i>Digestive and Liver Disease</i> , 2019, 51, 1074-1078.	0.4	32
76	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2216-2224.	0.9	32
77	Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 633-643.	0.9	31
78	Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. <i>Journal of Hepatology</i> , 2022, 77, 1359-1372.	1.8	30
79	Antimitochondrial Antibodies: from Bench to Bedside. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 166-177.	2.9	29
80	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. <i>Cancers</i> , 2020, 12, 3370.	1.7	28
81	Experimental liver models: From cell culture techniques to microfluidic organs-on-a-chip. <i>Liver International</i> , 2021, 41, 1744-1761.	1.9	28
82	Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence. <i>Liver International</i> , 2020, 40, 3117-3124.	1.9	27
83	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27
84	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2015, 47, 432-435.	0.4	26
85	The epigenetics of PBC: The link between genetic susceptibility and environment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 650-659.	0.7	26
86	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1705-1712.	1.9	26
87	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. <i>Immunity and Ageing</i> , 2011, 8, 12.	1.8	25
88	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. <i>BMC Gastroenterology</i> , 2012, 12, 92.	0.8	24
89	Apotopes and innate immune system: Novel players in the primary biliary cirrhosis scenario. <i>Digestive and Liver Disease</i> , 2013, 45, 630-636.	0.4	24
90	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191.	1.4	23

#	ARTICLE	IF	CITATIONS
91	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS ONE, 2016, 11, e0159612.	1.1	23
92	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators of Inflammation, 2015, 2015, 1-12.	1.4	22
93	Making Sense of Autoantibodies in Cholestatic Liver Diseases. Clinics in Liver Disease, 2016, 20, 33-46.	1.0	22
94	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. Immunobiology, 2015, 220, 1025-1029.	0.8	20
95	Changes in the Epidemiology of Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 429-441.	1.0	20
96	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Frontiers in Oncology, 2018, 8, 181.	1.3	19
97	Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World Journal of Gastroenterology, 2020, 26, 4900-4918.	1.4	19
98	Transcriptional Differences for COVID-19 Disease Map Genes between Males and Females Indicate a Different Basal Immunophenotype Relevant to the Disease. Genes, 2020, 11, 1447.	1.0	16
99	The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepatic Oncology, 2018, 5, HEP03.	4.2	14
100	Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. Vaccines, 2022, 10, 801.	2.1	13
101	Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C Increases Neutrophil and Monocyte Chemotaxis. Annals of the New York Academy of Sciences, 2009, 1173, 847-857.	1.8	11
102	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Digestive and Liver Disease, 2014, 46, 363-368.	0.4	11
103	Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma—a composite scenario. Hepatobiliary Surgery and Nutrition, 2018, 7, 130-133.	0.7	11
104	Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. Journal of Leukocyte Biology, 2020, 108, 715-721.	1.5	11
105	Safety of vedolizumab in liver transplant recipients: A systematic review. United European Gastroenterology Journal, 2019, 7, 875-880.	1.6	10
106	Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. Updates in Surgery, 2020, 72, 413-421.	0.9	9
107	Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury. Digestive and Liver Disease, 2022, 54, 722-726.	0.4	8
108	Is Liver Injury an Affordable Risk of Immune Checkpoint Inhibitor Therapy for Cancer?. Gastroenterology, 2018, 155, 2021-2023.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. <i>Cancers</i> , 2021, 13, 2070.	1.7	6
110	Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 933-936.	1.3	5
111	Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma different from that of hepatocellular carcinoma and mass-forming cholangiocarcinoma? A case-matched analysis. <i>Updates in Surgery</i> , 2020, 72, 671-679.	0.9	5
112	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	1.7	5
113	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. <i>World Journal of Gastroenterology</i> , 2022, 28, 1430-1443.	1.4	5
114	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. <i>Autoimmunity Highlights</i> , 2012, 3, 127-132.	3.9	4
115	Postsustained Virological Response Management in Hepatitis C Patients. <i>Seminars in Liver Disease</i> , 2020, 40, 233-239.	1.8	4
116	Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 839-843.	1.0	4
117	What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. <i>United European Gastroenterology Journal</i> , 2021, 9, 787-796.	1.6	4
118	High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels. <i>Liver International</i> , 2022, 42, 1692-1695.	1.9	4
119	Human Î²-Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e80.	1.3	3
120	Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. <i>Hepatology</i> , 2020, 72, 359-360.	3.6	3
121	COVID-19 and liver cancer clinical trials: Not everything is lost. <i>Liver International</i> , 2020, 40, 1541-1544.	1.9	3
122	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021, 28, 558-568.	1.0	3
123	Pembrolizumab-Induced Vanishing Bile Duct Syndrome: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 906-908.	0.3	3
124	Versatile Mass Spectrometry-Based Intraoperative Diagnosis of Liver Tumor in a Multiethnic Cohort. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4244.	1.3	3
125	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 570-574.	0.6	2
126	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. <i>Journal of Hepatology</i> , 2018, 68, S86.	1.8	2

#	ARTICLE	IF	CITATIONS
127	Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9342.	1.3	2
128	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
129	Is immunosuppression truly associated with worse outcomes in autoimmune hepatitis patients with COVID-19?. <i>Liver International</i> , 2022, 42, 274-276.	1.9	2
130	What Is an Autoantibody?. , 2014, , 13-20.		1
131	Hepatitis C virus eradication with direct antiviral agents and liver cancer recurrence: Is the best the enemy of the good?. <i>Liver International</i> , 2017, 37, 1110-1112.	1.9	1
132	No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. <i>Liver International</i> , 2018, 38, 2342.	1.9	1
133	Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 148-150.	0.7	1
134	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 5-6.	3.7	1
135	All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 51-53.	2.4	1
136	Survival After Liver Transplantation for Autoimmune Hepatitis: Are We Messing With the Immune System?. <i>Liver Transplantation</i> , 2020, 26, 861-862.	1.3	1
137	High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments. <i>Liver International</i> , 2021, 41, 1909-1912.	1.9	1
138	Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?. <i>Hepatology</i> , 2021, 74, 2307-2307.	3.6	1
139	Primary Biliary Cirrhosis and Autoimmune Cholangitis. , 2007, , 235-247.		1
140	Identifying medical professionals at risk for in-hospital COVID-19 infection: A snapshot during a "tsunami" highlighting unexpected risks. <i>Global Health & Medicine</i> , 2020, 2, 235-239.	0.6	1
141	Melatonin Inhibits In Vivo Cholangiocarcinoma Growth by Enhanced Biliary Expression of Serotonin N-Acetyltransferase (AANAT) the Key Enzyme Involved in Melatonin Synthesis. <i>Gastroenterology</i> , 2011, 140, S-910.	0.6	0
142	941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS – AN INTERNATIONAL, COLLABORATIVE ANALYSIS. <i>Journal of Hepatology</i> , 2013, 58, S388.	1.8	0
143	A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. <i>Digestive and Liver Disease</i> , 2016, 48, e233.	0.4	0
144	Geoeidemiology and the Impact of Sex on Autoimmune Diseases. , 2017, , 323-333.		0

#	ARTICLE	IF	CITATIONS
145	Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy. <i>Digestive and Liver Disease</i> , 2018, 50, 46-47.	0.4	0
146	Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection. <i>Digestive and Liver Disease</i> , 2018, 50, 8.	0.4	0
147	Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy. <i>Digestive and Liver Disease</i> , 2018, 50, 38-39.	0.4	0
148	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study. <i>Digestive and Liver Disease</i> , 2018, 50, 34-35.	0.4	0
149	Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 104-104.	1.5	0
150	Filamin a expression predicts early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, S382-S383.	1.8	0
151	The Epigenetics of Primary Biliary Cholangitis. , 2018, , 251-272.		0
152	Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection. <i>Journal of Hepatology</i> , 2018, 68, S425-S426.	1.8	0
153	SAT-493-Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e850-e851.	1.8	0
154	Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions. <i>Current Transplantation Reports</i> , 2019, 6, 134-145.	0.9	0
155	Lights and Shadows on Fibrates as Second-Line Therapy of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2019, 156, 1930-1931.	0.6	0
156	Coronary flow reserve is an innovative tool for the early detection of cardiovascular dysfunction in primary biliary cholangitis patients. <i>Digestive and Liver Disease</i> , 2019, 51, 549-550.	0.4	0
157	Global characterization of tumor infiltrate of Intrahepatic Cholangiocarcinoma by single cell sequencing. <i>Digestive and Liver Disease</i> , 2020, 52, e48-e49.	0.4	0
158	The metabolic plasticity of neoplastic cholangiocytes: perspective for target therapy of intrahepatic cholangiocarcinoma. <i>Digestive and Liver Disease</i> , 2020, 52, e5.	0.4	0
159	Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications. <i>Digestive and Liver Disease</i> , 2020, 52, e55.	0.4	0
160	Impact of HBV infection in HCV/HBV coinfecting patients treated with DAAs IN Northern Italy. <i>Digestive and Liver Disease</i> , 2020, 52, e19-e20.	0.4	0
161	Directly acting antivirals are safe and effective in HCV elderly patients: a multicenter real life study. <i>Digestive and Liver Disease</i> , 2020, 52, e28.	0.4	0
162	Small and Large Bile Ducts Intrahepatic Cholangiocarcinoma Classification: A Preliminary Feature-Based Study. <i>Lecture Notes in Computer Science</i> , 2021, , 237-244.	1.0	0

#	ARTICLE	IF	CITATIONS
163	Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma. European Journal of Surgical Oncology, 2022, , .	0.5	0
164	A change of paradigm in PBC: Pursuing normal alkaline phosphatase. EBioMedicine, 2022, 82, 104150.	2.7	0